Existing and emerging therapies for the treatment of invasive candidiasis and candidemia

References

• Kullberg BJ, Arendrup MC, Campion EW. Invasive Candidiasis. N Engl J Med. 2015 Oct 8;373(15):1445–1456.
   PubMed Web of Science ®Google Scholar
• Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004 Aug 1;39(3):309–317.
   PubMed Web of Science ®Google Scholar
• Lortholary O, Renaudat C, Sitbon K, et al. Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010). Intensive Care Med. 2014 Sep;40(9):1303–1312.
   PubMed Web of Science ®Google Scholar
• Marchetti O, Bille J, Fluckiger U, et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis. 2004 Feb 1;38(3):311–320.
   PubMed Web of Science ®Google Scholar
• Bongomin F, Gago S, Oladele RO, et al. Global and multi-national prevalence of fungal diseases-estimate precision. J Fungi (Basel). 2017 Oct 18;3(4):57.
   PubMedGoogle Scholar
• Webb BJ, Ferraro JP, Rea S, et al. Epidemiology and clinical features of invasive fungal infection in a US health care network. Open Forum Infect Dis. 2018 Aug;5(8):ofy187.
   PubMed Web of Science ®Google Scholar
• Andes DR, Safdar N, Baddley JW, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis. 2012 Apr;54(8):1110–1122.
   PubMed Web of Science ®Google Scholar
• Shields BE, Rosenbach M, Brown-Joel Z, et al. Angioinvasive fungal infections impacting the skin: background, epidemiology, and clinical presentation. J Am Acad Dermatol. 2019 Apr;80(4):869–880 e5.
   PubMed Web of Science ®Google Scholar
• Baddley JW, Benjamin DK Jr., Patel M, et al. Candida infective endocarditis. Eur J Clin Microbiol Infect Dis. 2008 Jul;27(7):519–529.
   PubMed Web of Science ®Google Scholar
• Sanchez-Portocarrero J, Perez-Cecilia E, Corral O, et al. The central nervous system and infection by Candida species. Diagn Microbiol Infect Dis. 2000 Jul;37(3):169–179.
   PubMed Web of Science ®Google Scholar
• Lagunes L, Rey-Perez A. What s new in intraabdominal candidiasis in critically ill patients, a review.Hosp Pract. 1995 2019Oct;47(4):171–176.
   Google Scholar
• Breazzano MP, Day HR Jr., Bloch KC, et al. Utility of ophthalmologic screening for patients with candida bloodstream infections: a systematic review. JAMA Ophthalmol. 2019 Jun 1;137(6):698–710.
   PubMed Web of Science ®Google Scholar
• Gow NA, van de Veerdonk FL, Brown AJ, et al. Candida albicans morphogenesis and host defence: discriminating invasion from colonization. Nat Rev Microbiol. 2011 Dec 12;10(2):112–122.
   PubMed Web of Science ®Google Scholar
• Guinea J. Global trends in the distribution of Candida species causing candidemia. Clin Microbiol Infect. 2014 Jun;20(6):5–10.
   Google Scholar
• Gonzalez-Lara MF, Ostrosky-Zeichner L. Invasive Candidiasis. Semin Respir Crit Care Med. 2020 Feb;41(1):3–12.
   PubMed Web of Science ®Google Scholar
• Cleveland AA, Harrison LH, Farley MM, et al. Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008-2013: results from population-based surveillance. PLoS One. 2015;10(3):e0120452.
   PubMed Web of Science ®Google Scholar
• Clancy CJ, Nguyen MH, Kraft CS. Diagnosing Invasive Candidiasis. J Clin Microbiol. 2018 May;56(5). 10.1128/JCM.01909-17.
   Web of Science ®Google Scholar
• Karageorgopoulos DE, Vouloumanou EK, Ntziora F, et al. beta-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis. 2011 Mar 15;52(6):750–770.
   PubMed Web of Science ®Google Scholar
• Mikulska M, Calandra T, Sanguinetti M, et al. The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the third European conference on infections in Leukemia. Crit Care. 2010;14(6):R222.
   PubMed Web of Science ®Google Scholar
• Martinez-Jimenez MC, Munoz P, Guinea J, et al. Potential role of Candida albicans germ tube antibody in the diagnosis of deep-seated candidemia. Med Mycol. 2014 Apr;52(3):270–275.
   PubMed Web of Science ®Google Scholar
• Fortun J, Meije Y, Buitrago MJ, et al. Clinical validation of a multiplex real-time PCR assay for detection of invasive candidiasis in intensive care unit patients. J Antimicrob Chemother. 2014 Nov;69(11):3134–3141.
   PubMed Web of Science ®Google Scholar
• Zacharioudakis IM, Zervou FN, Mylonakis E. T2 magnetic resonance assay: overview of available data and clinical implications. J Fungi (Basel). 2018 Apr 4;4(2):45.
   PubMedGoogle Scholar
• Clancy CJ, Nguyen MH. Non-culture diagnostics for invasive candidiasis: promise and unintended consequences. J Fungi (Basel). 2018 Feb 19;4(1):27.
   PubMedGoogle Scholar
• Arendrup MC, Patterson TF. Multidrug-resistant Candida: epidemiology, molecular mechanisms, and treatment. J Infect Dis. 2017 Aug 15; 216(suppl_3):S445–S451.
   PubMedGoogle Scholar
• Lockhart SR. Candida auris and multidrug resistance: defining the new normal. Fungal Genet Biol. 2019 Oct;131:103243.
   PubMed Web of Science ®Google Scholar
• Carolus H, Pierson S, Lagrou K, et al. Amphotericin B and other polyenes-discovery, clinical use, mode of action and drug resistance. J Fungi (Basel). 2020 Nov 27;6(4):321.
   PubMedGoogle Scholar
• Demin KA, Refeld AG, Bogdanova AA, et al. Mechanisms of Candida resistance to antimycotics and promising ways to overcome it: the role of probiotics. Probiotics Antimicrob Proteins. 2021 Mar 18;13:928–946.
   Web of Science ®Google Scholar
• Berkow EL, Lockhart SR. Activity of CD101, a long-acting echinocandin, against clinical isolates of Candida auris. Diagn Microbiol Infect Dis. 2018 Mar;90(3):196–197.
   PubMed Web of Science ®Google Scholar
• Soulountsi V, Schizodimos T, Kotoulas SC. Deciphering the epidemiology of invasive candidiasis in the intensive care unit: is it possible? Infection. 2021 Jun 16;49(6):1107.
   PubMed Web of Science ®Google Scholar
• Kahn JN, Garcia-Effron G, Hsu MJ, et al. Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob Agents Chemother. 2007 May;51(5):1876–1878.
   PubMed Web of Science ®Google Scholar
• Ahmad S, Alfouzan W. Candida auris: epidemiology, diagnosis, pathogenesis, antifungal susceptibility, and infection control measures to combat the spread of infections in healthcare facilities. Microorganisms. 2021 Apr 11;9(4):807.
   PubMed Web of Science ®Google Scholar
• Tortorano AM, Prigitano A, Morroni G, et al. Candidemia: evolution of drug resistance and novel therapeutic approaches. Infect Drug Resist. 2021;14:5543–5553.
   PubMed Web of Science ®Google Scholar
• Chapeland-Leclerc F, Bouchoux J, Goumar A, et al. Inactivation of the FCY2 gene encoding purine-cytosine permease promotes cross-resistance to flucytosine and fluconazole in Candida lusitaniae. Antimicrob Agents Chemother. 2005 Aug;49(8):3101–3108.
   PubMed Web of Science ®Google Scholar
• Colombo AL, Junior JNA, Guinea J. Emerging multidrug-resistant Candida species. Curr Opin Infect Dis. 2017 Dec;30(6):528–538.
   PubMed Web of Science ®Google Scholar
• Satoh K, Makimura K, Hasumi Y, et al. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009 Jan;53(1):41–44.
   PubMed Web of Science ®Google Scholar
• Lee WG, Shin JH, Uh Y, et al. First three reported cases of nosocomial fungemia caused by Candida auris. J Clin Microbiol. 2011 Sep;49(9):3139–3142.
   PubMed Web of Science ®Google Scholar
• Plachouras D, Lotsch F, Kohlenberg A, et al. Candida auris: epidemiological situation, laboratory capacity and preparedness in the European Union and European Economic Area*, January 2018 to May 2019. Euro Surveill. 2020 Mar;25(12):2000240.
   PubMedGoogle Scholar
• Chowdhary A, Voss A, Meis JF. Multidrug-resistant Candida auris: ‘new kid on the block’ in hospital-associated infections? J Hosp Infect. 2016 Nov;94(3):209–212.
   PubMed Web of Science ®Google Scholar
• Tsay S, Kallen A, Jackson BR, et al. Approach to the investigation and management of patients with Candida auris, an emerging multidrug-resistant yeast. Clin Infect Dis. 2018 Jan 6;66(2):306–311.
   PubMed Web of Science ®Google Scholar
• Ademe M, Girma F. Candida auris: from multidrug resistance to pan-resistant strains. Infect Drug Resist. 2020;13:1287–1294.
   PubMed Web of Science ®Google Scholar
• Osei Sekyere J. Candida auris: a systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen. Microbiologyopen. 2019 Aug;8(8):e00901.
   PubMed Web of Science ®Google Scholar
• Lockhart SR, Etienne KA, Vallabhaneni S, et al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis. 2017 Jan 15;64(2):134–140.
   PubMed Web of Science ®Google Scholar
• Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006 Jul 1;43(1):25–31.
   PubMed Web of Science ®Google Scholar
• Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005 Sep;49(9):3640–3645.
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of Candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016 Feb 15;62(4):e1–50.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Bassetti M, Calandra T, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012 Dec;18(7):19–37.
   PubMedGoogle Scholar
• Fanos V, Cataldi L. Amphotericin B-induced nephrotoxicity: a review. J Chemother. 2000 Dec;12(6):463–470.
   PubMed Web of Science ®Google Scholar
• Hamill RJ. Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs. 2013 Jun;73(9):919–934.
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, Sae-Tia S, Fries BC. Candidiasis and mechanisms of antifungal resistance. Antibiotics (Basel). 2020 Jun 9; 9(6):312.
   PubMed Web of Science ®Google Scholar
• Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet. 2005 Oct 22-28;366(9495):1435–1442.
   PubMed Web of Science ®Google Scholar
• Fasciana T, Cortegiani A, Ippolito M, et al. Candida auris: an overview of how to screen, detect, test and control this emerging pathogen. Antibiotics (Basel). 2020 Nov 5;9(11):778.
   PubMed Web of Science ®Google Scholar
• Barantsevich N, Barantsevich E. Diagnosis and Treatment of Invasive Candidiasis. Antibiotics (Basel). 2022 May 26; 11(6):718.
   PubMed Web of Science ®Google Scholar
• Nivoix Y, Ledoux MP, Herbrecht R. Antifungal therapy: new and evolving therapies. Semin Respir Crit Care Med. 2020 Feb;41(1):158–174.
   PubMed Web of Science ®Google Scholar
• Debruyne D, Ryckelynck JP. Clinical pharmacokinetics of fluconazole. Clin Pharmacokinet. 1993 Jan;24(1):10–27.
   PubMed Web of Science ®Google Scholar
• Purkins L, Wood N, Ghahramani P, et al. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother. 2002 Aug;46(8):2546–2553.
   PubMed Web of Science ®Google Scholar
• Schmitt-Hoffmann A, Desai A, Kowalski D, et al. Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH. Int J Clin Pharmacol Ther. 2016 Aug;54(8):572–580.
   PubMed Web of Science ®Google Scholar
• Lipp HP. Antifungal agents–clinical pharmacokinetics and drug interactions. Mycoses. 2008;51 Suppl 1(s1):7–18.
   PubMedGoogle Scholar
• Barchiesi F, Spreghini E, Tomassetti S, et al. Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. Antimicrob Agents Chemother. 2006 Aug;50(8):2719–2727.
   PubMed Web of Science ®Google Scholar
• Wagner C, Graninger W, Presterl E, et al. The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications. Pharmacology. 2006;78(4):161–177.
   PubMed Web of Science ®Google Scholar
• Vazquez JA, Sobel JD. Anidulafungin: a novel echinocandin. Clin Infect Dis. 2006 Jul 15;43(2):215–222.
   PubMed Web of Science ®Google Scholar
• Chandrasekar PH, Sobel JD. Micafungin: a new echinocandin. Clin Infect Dis. 2006 Apr 15;42(8):1171–1178.
   PubMed Web of Science ®Google Scholar
• Bellmann R, Smuszkiewicz P. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection. 2017 Dec;45(6):737–779.
   PubMed Web of Science ®Google Scholar
• Wall G, Lopez-Ribot JL. Current antimycotics, new prospects, and future approaches to antifungal therapy. Antibiotics (Basel). 2020 Jul 25; 9(8):445.
   PubMed Web of Science ®Google Scholar
• Ruhnke M, Paiva JA, Meersseman W, et al. Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients. Clin Microbiol Infect. 2012 Jul;18(7):680–687.
   PubMed Web of Science ®Google Scholar
• Benedict K, Jackson BR, Chiller T, et al. Estimation of direct healthcare costs of fungal diseases in the United States. Clin Infect Dis. 2019 May 17;68(11):1791–1797.
   PubMed Web of Science ®Google Scholar
• Seiler GT, Ostrosky-Zeichner L. Investigational agents for the treatment of resistant yeasts and molds. Curr Fungal Infect Rep. 2021 May;28:1–12.
   Google Scholar
• Georgopapadakou NH, Tkacz JS. The fungal cell wall as a drug target. Trends Microbiol. 1995 Mar;3(3):98–104.
   PubMedGoogle Scholar
• Lorenz MC, Fink GR. Life and death in a macrophage: role of the glyoxylate cycle in virulence. Eukaryot Cell. 2002 Oct;1(5):657–662.
   PubMed Web of Science ®Google Scholar
• Lengeler KB, Davidson RC, D’Souza C, et al. Signal transduction cascades regulating fungal development and virulence. Microbiol Mol Biol Rev. 2000 Dec;64(4):746–785.
   PubMed Web of Science ®Google Scholar
• Mota Fernandes C, Dasilva D, Haranahalli K, et al. The future of antifungal drug therapy: novel compounds and targets. Antimicrob Agents Chemother. 2021 Jan 20;65(2):e01719–20.
   PubMed Web of Science ®Google Scholar
• Hokken MWJ, Zwaan BJ, Melchers WJG, et al. Facilitators of adaptation and antifungal resistance mechanisms in clinically relevant fungi. Fungal Genet Biol. 2019 Nov;132:103254.
   PubMed Web of Science ®Google Scholar
• Aigner M, Lass-Florl C. Encochleated amphotericin B: is the oral availability of amphotericin B finally reached? J Fungi (Basel). 2020 May 18;6(2):66.
   PubMedGoogle Scholar
• Kibathi LKP, Lionakis M, Urban A, et al. A phase IIa efficacy, safety, tolerability and pharmacokinetic (pk) study of encochleated amphotericin b in patients with mucocutaneous (esophogeal, oropharyngeal, vulvovaginal) candidiasis who are refractory or intolerant to standard non-intravenous therapies. Open Forum Infect Dis. 2018;5:S435–S436.
   Google Scholar
• Warrilow AG, Hull CM, Parker JE, et al. The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme. Antimicrob Agents Chemother. 2014 Dec;58(12):7121–7127.
   PubMed Web of Science ®Google Scholar
• Schell WA, Jones AM, Garvey EP, et al. Fungal CYP51 inhibitors VT-1161 and VT-1129 exhibit strong in vitro activity against Candida glabrata and C. krusei isolates clinically resistant to azole and echinocandin antifungal compounds. Antimicrob Agents Chemother. 2017 Mar;61(3):e01817–16.
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Patterson HP, Tran BH, et al. Fungal-specific Cyp51 inhibitor VT-1598 demonstrates in vitro activity against Candida and Cryptococcus species, endemic fungi, including Coccidioides species, Aspergillus species and Rhizopus arrhizus. J Antimicrob Chemother. 2018 Feb 1;73(2):404–408.
   PubMed Web of Science ®Google Scholar
• Nishimoto AT, Wiederhold NP, Flowers SA, et al. In vitro activities of the novel investigational tetrazoles VT-1161 and VT-1598 compared to the triazole antifungals against azole-resistant strains and clinical isolates of Candida albicans. Antimicrob Agents Chemother. 2019 Jun;63(6):e00341–19.
   PubMed Web of Science ®Google Scholar
• Brand SR, Degenhardt TP, Person K, et al. A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 2018 Jun;218(6):624 e1–624 e9.
   PubMed Web of Science ®Google Scholar
• Rudramurthy SM, Colley T, Abdolrasouli A, et al. In vitro antifungal activity of a novel topical triazole PC945 against emerging yeast Candida auris. J Antimicrob Chemother. 2019 Oct 1;74(10):2943–2949.
   PubMed Web of Science ®Google Scholar
• Garcia-Effron G. Rezafungin-mechanisms of action, susceptibility and resistance: similarities and differences with the other echinocandins. J Fungi (Basel). 2020 Nov 1;6(4):262.
   PubMedGoogle Scholar
• Thompson GR, Soriano A, Skoutelis A, et al. Rezafungin versus caspofungin in a Phase 2, randomized, double-blind study for the treatment of Candidemia and invasive candidiasis- the STRIVE trial. Clin Infect Dis. 2021 Sep 21;73(11):e3647–e3655.
   PubMed Web of Science ®Google Scholar
• Heasley BH, Pacofsky GJ, Mamai A, et al. Synthesis and biological evaluation of antifungal derivatives of enfumafungin as orally bioavailable inhibitors of beta-1,3-glucan synthase. Bioorg Med Chem Lett. 2012 Nov 15;22(22):6811–6816.
   PubMed Web of Science ®Google Scholar
• Ghannoum M, Arendrup MC, Chaturvedi VP, et al. Ibrexafungerp: a novel oral triterpenoid antifungal in development for the treatment of Candida auris infections. Antibiotics (Basel). 2020 Aug 25;9(9):539.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Rhomberg PR, et al. Differential activity of the oral glucan synthase inhibitor SCY-078 against wild-type and echinocandin-resistant strains of Candida species. Antimicrob Agents Chemother. 2017 Aug;61(8):e00161–17.
   PubMed Web of Science ®Google Scholar
• Davis MR, Donnelley MA, Thompson GR. Ibrexafungerp: a novel oral glucan synthase inhibitor. Med Mycol. 2020 Jul 1;58(5):579–592.
   PubMed Web of Science ®Google Scholar
• Spec A, Pullman J, Thompson GR, et al. MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis. J Antimicrob Chemother. 2019 Oct 1;74(10):3056–3062.
   PubMed Web of Science ®Google Scholar
• Miyazaki M, Horii T, Hata K, et al. In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds. Antimicrob Agents Chemother. 2011 Oct;55(10):4652–4658.
   PubMed Web of Science ®Google Scholar
• Shaw KJ, Ibrahim AS. Fosmanogepix: a review of the first-in-class broad spectrum agent for the treatment of invasive fungal infections. J Fungi (Basel). 2020 Oct 22;6(4):239.
   PubMedGoogle Scholar
• Hager CL, Larkin EL, Long L, et al. In vitro and in vivo evaluation of the antifungal activity of APX001A/APX001 against Candida auris. Antimicrob Agents Chemother. 2018 Mar;62(3):e02319–17.
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Najvar LK, Shaw KJ, et al. Efficacy of delayed therapy with fosmanogepix (APX001) in a murine model of candida auris invasive Candidiasis. Antimicrob Agents Chemother. 2019 Nov;63(11):e01120–19.
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Najvar LK, Jaramillo R, et al. The novel arylamidine T-2307 demonstrates in vitro and in vivo activity against Candida auris. Antimicrob Agents Chemother. 2020 Feb 21;64(3):e02198–19.
   PubMed Web of Science ®Google Scholar
• Gintjee TJ, Donnelley MA, Thompson GR 3rd. Aspiring antifungals: review of current antifungal pipeline developments. J Fungi (Basel). 2020 Feb 25;6(1):28.
   PubMedGoogle Scholar
• Yamashita K, Miyazaki T, Fukuda Y, et al. The Novel arylamidine T-2307 selectively disrupts yeast mitochondrial function by inhibiting respiratory chain complexes. Antimicrob Agents Chemother. 2019 Aug;63(8):e00374–19.
   PubMed Web of Science ®Google Scholar
• Wiederhold NP. Review of T-2307, an investigational agent that causes collapse of fungal mitochondrial membrane potential. J Fungi (Basel). 2021 Feb 11;7(2):130.
   PubMedGoogle Scholar
• Chapman T, Kinsman O, Houston J. Chitin biosynthesis in Candida albicans grown in vitro and in vivo and its inhibition by nikkomycin Z. Antimicrob Agents Chemother. 1992 Sep;36(9):1909–1914.
   PubMed Web of Science ®Google Scholar
• Bentz ML, Nunnally N, Lockhart SR, et al. Antifungal activity of nikkomycin Z against Candida auris. J Antimicrob Chemother. 2021 May 12;76(6):1495–1497.
   PubMed Web of Science ®Google Scholar
• Larwood DJ. Nikkomycin Z-ready to meet the promise? J Fungi (Basel). 2020 Oct 30; 6(4):261.
   PubMedGoogle Scholar
• Li RK, Rinaldi MG. In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole. Antimicrob Agents Chemother. 1999 Jun;43(6):1401–1405.
   PubMed Web of Science ®Google Scholar
• Nix DE, Swezey RR, Hector R, et al. Pharmacokinetics of nikkomycin Z after single rising oral doses. Antimicrob Agents Chemother. 2009 Jun;53(6):2517–2521.
   PubMed Web of Science ®Google Scholar
• Liu Q, Guo X, Jiang G, et al. NADPH-cytochrome P450 reductase Ccr1 Is a target of tamoxifen and participates in its antifungal activity via regulating cell wall integrity in fission yeast. Antimicrob Agents Chemother. 2020 Aug 20;64(9):e00079–20.
   PubMed Web of Science ®Google Scholar
• Butts A, Koselny K, Chabrier-Rosello Y, et al. Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo. mBio. 2014 Feb 11;5(1):e00765–13.
   PubMed Web of Science ®Google Scholar
• Ngan NTT, Mai NTH, Tung NLN, et al. A randomized open label trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis. Wellcome Open Res. 2019;4:8.
   PubMedGoogle Scholar
• Costa Silva RA, da Silva CR, de Andrade Neto JB, et al. In vitro anti-Candida activity of selective serotonin reuptake inhibitors against fluconazole-resistant strains and their activity against biofilm-forming isolates. Microb Pathog. 2017 Jun;107:341–348.
   PubMed Web of Science ®Google Scholar
• Gowri M, Jayashree B, Jeyakanthan J, et al. Sertraline as a promising antifungal agent: inhibition of growth and biofilm of Candida auris with special focus on the mechanism of action in vitro. J Appl Microbiol. 2020 Feb;128(2):426–437.
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Patterson TF, Srinivasan A, et al. Repurposing auranofin as an antifungal: in vitro activity against a variety of medically important fungi. Virulence. 2017 Feb 17;8(2):138–142.
   PubMed Web of Science ®Google Scholar
• She P, Liu Y, Wang Y, et al. Antibiofilm efficacy of the gold compound auranofin on dual species biofilms of Staphylococcus aureus and Candida sp. J Appl Microbiol. 2020 Jan;128(1):88–101.
   PubMed Web of Science ®Google Scholar
• Roder C, Thomson MJ. Auranofin: repurposing an old drug for a golden new age. Drugs R D. 2015 Mar;15(1):13–20.
   PubMed Web of Science ®Google Scholar
• Peyclit L, Yousfi H, Rolain JM, et al. Drug repurposing in medical mycology: identification of compounds as potential antifungals to overcome the emergence of multidrug-resistant fungi. Pharmaceuticals (Basel). 2021 May 20;14(5):488.
   PubMedGoogle Scholar
• Billamboz M, Fatima Z, Hameed S, et al. Promising drug candidates and new strategies for fighting against the emerging superbug Candida auris. Microorganisms. 2021 Mar 18;9(3):634.
   PubMed Web of Science ®Google Scholar